Accuray Incorporated (ARAY) FinancialsARAYAccuray Incorporated

Accuray Incorporated (ARAY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Service, accounting for 52.6% of total sales, equivalent to $55.13M. Another important revenue stream is Product. Understanding this composition is critical for investors evaluating how ARAY navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Accuray Incorporated maintains a gross margin of 34.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.21%, while the net margin is -1.92%. These profitability ratios, combined with a Return on Equity (ROE) of -80.08%, provide a clear picture of how effectively ARAY converts its operational activities into shareholder value.

In the context of the broader market, ARAY competes directly with industry leaders such as RMTI and XTLB. With a market capitalization of $32.71M, it holds a significant position in the sector. When comparing efficiency, ARAY's gross margin of 34.76% stands against RMTI's 18.24% and XTLB's N/A. Such benchmarking helps identify whether Accuray Incorporated is trading at a premium or discount relative to its financial performance.

Accuray's total revenue for Q4 2026 was $100.9 million, a 21% decrease year-over-year, while the gross margin has fluctuated, recently reported at 34.76%. However, the company continues to face net losses, with a net income of -$1.94 million in Q4 2026.